EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)

Alain Vergnenegre, Isabelle Monnet, Charles Ricordel, Acya Bizieux, Hubert Curcio, Marie Bernardi, Romain Corre, Florian Guisier, Stéphane Hominal, Gwenaelle Le Garff, Olivier Bylicki, Chrystèle Locher und 4 weitere

Lung Cancer · 2023

DOI: 10.1016/j.lungcan.2023.02.020 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Lung Cancer, 2023. Verfasst von Alain Vergnenegre und 15 weiteren Autor:innen. Beteiligte Einrichtung: CHU Dupuytren, Limoges, France. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: F. Hoffmann-La Roche Ltd, Pierre Fabre Médicament SAS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To evaluate the safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage IV non-small-cell lung cancer. METHODS: This was a multicenter, open-label, single-arm Phase II study performed in patients with advanced NSCLC without activating EGFR mutation or ALK rearrangement who progressed after first-line platinum-doublet chemotherapy. Combination treatment was atezolizumab (1200 mg IV day 1, every 3 weeks) and oral vinorelbine (40 mg, 3 times by week). The primary outcome was progression-free survival (PFS) during the 4-month follow-up from the first dose of treatment. Statistical analysis was based on the exact single-stage Phase II design defined by A'Hern. Based on literature data, the Phase III trial threshold was set at 36 successes in 71 patients. RESULTS: 71 patients were analyzed (median age, 64 years; male, 66.2%; ex-smokers/active smokers, 85.9%; ECOG performance status 0-1, 90.2%; non-squamous NSCLC, 83.1%; PD-L1 ≥ 50%, 4.4%). After a median follow-up of 8.1 months from treatment initiation, 4-month PFS rate was 32% (95% CI, 22-44), i.e. 23 successes out 71 patients. OS rate was 73.2% at 4 months and 24.3% at 24 months. Median PFS and OS were 2.2 (95% CI, 1.5-3.0) months and 7.9 (95% CI, 4.8-11.4) months, respectively. Overall response rate and disease control rate at 4 months were 11% (95% CI, 5-21) and 32% (95% CI, 22-44), respectively. No safety signal was evidenced. CONCLUSION: Metronomic oral vinorelbine-atezolizumab in the second-line setting did not achieve the predefined PFS threshold. No new safety signal was reported for vinorelbine-atezolizumab combination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansMaleMiddle AgedVinorelbineAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

AtezolizumabImmune check-point inhibitorsMetastatic cancerNon-small cell lung cancerPhase II trialVinorelbine

Substanzen

VinorelbineatezolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • CHU Dupuytren, Limoges, France.
  • CHI Créteil, France.
  • CHU Pontchaillou, Rennes, France.
  • CHD Les Oudairies, La Roche-sur-Yon, France.
  • Centre François Baclesse, Caen, France.
  • CH Aix-en-Provence, France.

Förderung

  • F. Hoffmann-La Roche Ltd
  • Pierre Fabre Médicament SAS

Zitieren

APA

Vergnenegre, A., Monnet, I., Ricordel, C., Bizieux, A., Curcio, H., Bernardi, M., Corre, R., Guisier, F., Hominal, S., Le Garff, G., Bylicki, O., Locher, C., Geier, M., Chouaïd, C., Robinet, G., & GFPC team (2023). Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo). Lung Cancer. https://doi.org/10.1016/j.lungcan.2023.02.020

Vancouver

Vergnenegre A, Monnet I, Ricordel C, Bizieux A, Curcio H, Bernardi M, et al. Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo). Lung Cancer. 2023. doi:10.1016/j.lungcan.2023.02.020

BibTeX
@article{Vergnenegre2023,
  author = {Vergnenegre, Alain and Monnet, Isabelle and Ricordel, Charles and Bizieux, Acya and Curcio, Hubert and Bernardi, Marie and Corre, Romain and Guisier, Florian and Hominal, Stéphane and Le Garff, Gwenaelle and Bylicki, Olivier and Locher, Chrystèle and Geier, Margaux and Chouaïd, Christos and Robinet, Gilles and GFPC team, GFPC team},
  title = {Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)},
  journal = {Lung Cancer},
  year = {2023},
  doi = {10.1016/j.lungcan.2023.02.020}
}
Kostenlos starten →